CSIMarket
 

Candel Therapeutics Inc   (CADL)
Other Ticker:  
 

Candel Therapeutics Inc 's

Competitiveness


 

CADL Sales vs. its Competitors Q3 2023







Revenue Growth Comparisons




Net Income Comparison




<<  CADL Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Candel Therapeutics Inc Contracts

Candel Therapeutics Pioneers Groundbreaking Immunotherapies for Pancreatic and Brain Cancer Treatment

Candel Therapeutics, a clinical-stage biopharmaceutical company focused on the development of innovative multimodal biological immunotherapies, has achieved significant milestones in the treatment of pancreatic and brain cancers. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Candel's most advanced candidate, CAN-2409, for pancreatic cancer treatment. Additionally, promising results from a Phase 2 trial of CAN-2409 in non-metastatic pancreatic cancer patients have been reported. Furthermore, Candel's herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, has shown promising outcomes in an ongoing Phase 1b clinical trial for r...

Revolutionizing Pancreatic Cancer Treatment: The Pivotal Role of Candel?s CAN-2409

In an ongoing stride towards innovative cancer treatments, Candel Therapeutics, Inc. - a clinical stage biopharmaceutical firm committed to developing multimodal biological immunotherapies to counter cancer, recently shared promising interim survival data from their ongoing randomized phase 2 clinical trial of the complex CAN-2409 therapy employed to treat non-metastatic pancreatic cancer.Dedicated to the mission of battling cancer, Candel's recent announcements highlight the positive interim results from the clinical trial of CAN-2409 coupled with valacyclovir (prodrug), which is then followed by a standard of care (SoC) chemoradiation and resection. This cutting-edge treatment has primarily been designed t...

Promising Update on the Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

Candel Therapeutics, a clinical stage biopharmaceutical company, recently presented updated data from an ongoing phase 1b clinical trial of their viral immunotherapy candidate, CAN-3110, during the 5th Glioblastoma Drug Development Summit in Boston, Massachusetts. This article aims to ly outline the key facts and implications of the presentation, shedding light on the potential advancements in the treatment of recurrent high-grade glioma (rHGG).Background:Candel Therapeutics is focused on developing and commercializing viral immunotherapies primarily targeting cancer, including their candidate CAN-3110. This therapy utilizes a replication-competent herpes simplex virus-1 (HSV-1) to harness the patient's immu...

FDA Accelerates Approval for Candel Therapeutics' Pioneering Pancreatic Cancer Treatment, CAN-2409


NEEDHAM, Mass. ?? Candel Therapeutics, a biopharmaceutical company based in Massachusetts, announced a significant milestone in its effort to develop an effective treatment for pancreatic ductal adenocarcinoma (PDAC). The Food and Drug Administration (FDA) has granted Fast Track Designation to the company's lead investigational drug CAN-2409, a promising new addition to the global fight against pancreatic cancer.
The FDA Fast Track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The designation reflects the potential of CAN-2409 to make a significant positive difference for those diagnosed with pancreat...





Who are Candel Therapeutics Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com